NorthWest Biotherapeutics Inc (NWBO)

[trocprofit]

"that in this trial the control arm 99 outperforms the control arms of the 3 comparison trials, for whatever reason."

I believe it is because almost all crossed over. So, even though they likely started treatment later than they would have as part of the treatment arm, they probably still got benefits that outperform SOC. IMO.

So, separating the control/crossover arm and comparing that to contemporaneous trials, probably an improvement over last reported data.

In other words, no more confoundment with crossover data. The pure treatment arm improves by an even larger amount from the last blended/blinded data released. Based on historical SOC results, it is almost 100% assured, statistically speaking, for the matured data we have now to be better than the last blinded/blended data.